OncoSTING
PRIVATE
STATUS
Early Stage VC
LATEST DEAL TYPE
$150K
LATEST DEAL AMOUNT
2
INVESTORS
Description
Developer of therapies intended to cure bladder cancer. The company is developing novel bladder cancer therapies that work by combining the potency of standard BCG immunotherapy with long-lived delivery of potent STING agonists, enabling doctors to cure bladder cancer with reduced adverse events associated with traditional BCG.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
- Baltimore, MD
- United States
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore OncoSTING’s full profile, request a free trial.
OncoSTING Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC | 02-Jul-2019 | $150K | 00000 | Completed | Startup | |
| 2. Grant | 01-Jul-2018 | Completed | Startup | |||
| 1. Grant | 23-Feb-2018 | Completed | Startup |
OncoSTING Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Johns Hopkins University Endowment | Limited Partner | 000 0000 | 000000 0 | |||
| TEDCO | Venture Capital | Minority | 000 0000 | 000000 0 |